Free tool
FAERS Monitor: Pentam
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019264 or its brand name (Pentam, Pentamidine Isethionate). Reports on generic versions are filed under their own applications.
Reports
1,115
Serious
1,019
91% of reports
Hospitalization
557
Death reported
201
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia133
- pyrexia126
- off label use87
- aplastic anaemia77
- neutropenia73
- diarrhoea72
- mucosal inflammation57
- pneumonia57
- sepsis54
- pancytopenia52
- dyspnoea48
- nausea48
- thrombocytopenia47
- vomiting47
- platelet count decreased42
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 19 |
| 2006 | 45 |
| 2007 | 45 |
| 2008 | 38 |
| 2009 | 64 |
| 2010 | 107 |
| 2011 | 61 |
| 2012 | 51 |
| 2013 | 25 |
| 2014 | 12 |
| 2015 | 16 |
| 2016 | 35 |
| 2017 | 23 |
| 2018 | 24 |
| 2019 | 49 |
| 2020 | 69 |
| 2021 | 89 |
| 2022 | 95 |
| 2023 | 38 |
| 2024 | 90 |
| 2025 | 69 |
| 2026 | 40 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aplastic anaemiaSignal | 77 | 282.3 | 227.1 | 20,991 |
| mucosal inflammationSignal | 57 | 41.2 | 32.0 | 2,191 |
| febrile neutropeniaSignal | 133 | 37.9 | 32.3 | 4,746 |
| pancytopeniaSignal | 52 | 17.6 | 13.5 | 797 |
| neutropeniaSignal | 73 | 10.1 | 8.1 | 595 |
| sepsisSignal | 54 | 9.1 | 7.0 | 385 |
| thrombocytopeniaSignal | 47 | 7.9 | 6.0 | 279 |
| platelet count decreasedSignal | 42 | 7.4 | 5.5 | 229 |
| pyrexiaSignal | 126 | 6.9 | 5.8 | 636 |
| pneumoniaSignal | 57 | 3.3 | 2.6 | 92 |
| diarrhoeaSignal | 72 | 2.1 | 1.7 | 42 |
| vomiting | 47 | 1.9 | 1.4 | 19 |
| off label use | 87 | 1.9 | 1.5 | 36 |
| dyspnoea | 48 | 1.6 | 1.2 | 10 |
| nausea | 48 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.